The particulars: 99.1% · semaglutide.
I would rather understand the derivation than memorise the outcome.
Two people I asked gave two answers that differ by a factor of ten, which is suggestive.
Can someone show the working rather than just the answer?
99.1 per cent is at the top of what stepwise synthesis delivers on a chain this long, and it is reachable rather than fictional. Every coupling is high-yielding and none is quantitative, so the deletion and truncation sequences that survive purification are what occupies the remaining 0.9 per cent. Above roughly 98 per cent you are fighting the purification rather than the synthesis, which is why a 99.1 per cent figure on semaglutide deserves a method question — column, gradient, wavelength — rather than either belief or dismissal.
Purity is a method-dependent figure, and that is not a limitation of the measurement, it is a property of what the measurement actually answers.
Gradient slope controls resolution, and gentler slopes resolve co-eluting impurities into separate peaks — so the better method reports the worse purity number.
Tailing factor measures peak shape, and a badly tailing peak spreads into the region where small impurities live, forcing tangent-skim integration that assigns tail area to the main peak.
The Arrhenius relationship for peptide degradation is the basis of accelerated stability testing and also governs how quickly methods drift with temperature.
I would be careful about over-reading a single measurement — treat it as a data point, not as ground truth.
If you are ranking vendors, specify a method and have all samples tested at the same place.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsRead the chromatogram before you read the number, because the number without the trace is not a measurement, it is a claim.
Detection wavelength matters because 214 nm sees the peptide backbone while 280 nm sees only aromatic side chains — so truncation impurities lacking a tryptophan are invisible at 280 nm.
Mobile phase additive choice affects ionisation and peak shape — TFA gives sharp peaks but suppresses mass spectrometry signal, formic acid gives worse peaks but preserves signal.
Worth noting that method standardisation is poor in the research-grade space compared to pharmaceutical work, so identical-looking methods can produce different results.
Compare purity within a single laboratory on the same method, never across laboratories.
Understanding purity requires separating the chemistry from the method from the reporting convention, and the three are not independent.
Buffer versus acid in the mobile phase changes the ionisation state of basic and acidic residues, shifting retention and selectivity — same vial, potentially different separation.
On the detail: sample solvent strength affects peak shape — if you inject in strong solvent on a gradient starting in weak solvent, the solvent peak can distort your main peak or create a false shoulder.
Proline conformer interconversion kinetics are well-characterised and the half-life is of the same order as the chromatographic peak width at room temperature.
The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.
Stated carefully, area percentage is not mass percentage, and conflating the two is the most common misreading of a purity figure.
Integration of the shoulder — whether you use perpendicular drop or tangent skim — determines what area gets assigned to the main peak versus the impurity table.
Inter-laboratory studies on identical peptide material routinely find half-a-per-cent to a full-per-cent spreads in reported purity on the same sample.
If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.
Start from what the detector sees, because that tells you what the number means.
Mass on column affects detector linearity and peak overlap — overloading broadens peaks and hides neighbours, while underloading improves resolution but loses sensitivity.
The ICH Q3A impurity thresholds and the relevant pharmacopoeial chapters all specify method validation requirements that almost no research-grade certificate claims to meet.
One qualification: achieving purity above roughly 98 per cent on a 30-residue peptide is fighting the chemistry of synthesis, not the quality of the purification.
In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.